Intraprocedural

Phase 3Small molecule

CCMH Lahore Medical College and Institute of Dentistry

Intraprocedural is one of 3 small molecule programs targeting Simethicone. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

SimethiconeActive, not recruiting

SimethiconePhase 3

Active, not recruiting

Competition

Competitive Landscape

3 competitors in Simethicone

#DrugCompanyPhaseTrials

Intraprocedural

CCMH Lahore Medical College and Institute of Dentistry

Phase 3

1 2

Simethicone Plus NAC

AAsian Institute of Gastroenterology, India

Preclinical

1 3

N Acetyl Cysteine

TTanta University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Simethicone1 trial

Effects of Pre-procedure and Intra-procedure Simethicone and Dicyclomine Administration in Improving Quality of Endoscopic Reterograde Cholangipancreaticography (ERCP)

Active, not recruiting·—·Phase 4·NCT07461389·90 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Intraprocedural. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Intraprocedural compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Intraprocedural. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — CMH Lahore Medical College and Institute of Dentistry company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: CCMH Lahore Medical College and Institute of Dentistry

Intraprocedural

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Simethicone1 trial

References

Drug Info

Quick Facts

Related News